Bahasa

   Home      Contact

JOURNAL/ ARTICLES

JOURNAL

Systemic Lupus Erythematosus (Medical Progress, May 2002)
John Darmawan, MD, PhD, FACR
 Download
 

Reduced Burden of Disease and Improved Outcome of Patients with Rheumatoid Factor Positive Rheumatoid Arthritis Compared with Dropouts. A 10 Year Observational Study (The Journal of Rheumatology, Aug 2003)
JOHN DARMAWAN, JOHANNES J. RASKER, and HENDRI NURALIM
 Download

Ten-Year Radiographic Outcome in Patients with Rheumatoid Factor Positive Rheumatoid Arthritis Treated with Aggressive Immunosuppressive Combination Therapy Study (The Journal of Rheumatology)
JOHN DARMAWAN, JOHANNES J. RASKER, and HENDRI NURALIM
 Download

The Effect of Control and Self-Medication of Chronic Gout in a Developing Country. Outcome After 10 Years (The Journal of Rheumatology)
JOHN DARMAWAN, JOHANNES J. RASKER, and HENDRI NURALIM
 Download

 

 

ARTICLES

WHO-ILAR COPCORD Perspectives Past, Present,
and Future (The Journal of Rheumatology, Nov 2003)
JOHN DARMAWAN, MD. & KENNETH D. MUIRDEN, MD.
 Download

A review of constitutional changes in APLAR (APLAR Journal of Rheumatology 2003; 6: 114)
JOHN DARMAWAN, MD.
 Download

Interpretation of 10 years control of chronic gout
Download

 

  Email This Page   Print This Page
 
NEWS & EVENTS

LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

16.11.2005
MabThera – a unique approach providing lasting benefits for patients with rheumatoid arthritis

Comprehensive long-term clinical success achieved in difficult-to-treat patients following just two administrations, two weeks apart
 › more
 
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

06.09.2005
Roche files first rheumatoid arthritis indication for MabThera in Europe

MabThera: a medicine used to treat non-Hodgkin's lymphoma

MabThera delivers significant and sustained relief from symptoms in patients with difficult-to-treat rheumatoid arthritis.
› more
 
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

06.04.2005
MabThera significantly improves symptoms in patients with rheumatoid arthritis who inadequately responded to anti-TNFα therapies

Third large randomised trial to evaluate efficacy and safety of MabThera in RA

Roche, Genentech and Biogen Idec announced today that REFLEX1, a pivotal Phase III study of MabThera (rituximab), successfully met its primary endpoint in the group of patients with the most difficult-to-treat rheumatoid arthritis (RA).
 › more

Legal Disclamer

Legal Disclaimer

Copyright ©WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases.

This Web site was developed in 2005 as a service provided by the WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases. This Web site provides selected information available about lupus and arthritis. It is important that public see a healthcare professional for detailed information about medical conditions and treatment. This information is not intended to be a substitute for the advice of a healthcare professional, or a recommendation for any particular treatment plan. The WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases has made and will continue to make efforts to include accurate and up-to-date information on this Web site.

If you have any questions, please contact us:
Webmaster
Phone: 62-24-8447-345
Fax: 62-24-8310-028
admin@LupusArthritisIndonesia.org
 


Supported by PT Roche Indonesia